These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 4633969)

  • 1. Preparation and assay of horse anti-Pseudomonas serum and -globulin in mice.
    Laborde HF; De Fajardo CL
    Prog Immunobiol Stand; 1971; 5():419-24. PubMed ID: 4633969
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-linked immunosorbent assay for detection of antibody to Pseudomonas aeruginosa and measurement of antibody titer in horse serum.
    Ueda Y; Sanai Y; Homma JY
    Am J Vet Res; 1982 Jan; 43(1):55-60. PubMed ID: 6807144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
    Meitert E; Meitert T; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
    [No Abstract]   [Full Text] [Related]  

  • 5. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 6. Experimental immunization with attenuated mutants of Pseudomonas aeruginosa.
    Syeklocha D
    Can J Microbiol; 1973 May; 19(5):573-80. PubMed ID: 4196781
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
    Grochowski J; Bilinska M; Stankiewicz D; Arkusiewicz E
    Pol Przegl Chir; 1979 Jun; 51(6):623-7. PubMed ID: 116210
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic effect of immune gamma-globulin fraction on protection by antibiotic against corneal ulcers in experimental mice infected with Pseudomonas aeruginosa.
    Kawaharajo K; Homma JY
    Jpn J Exp Med; 1976 Jun; 46(3):155-65. PubMed ID: 822190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunization of burned patients with a new multivalent Staphylococcus-Pseudomonas vaccine.
    Sachs A
    Prog Immunobiol Stand; 1971; 5():428-32. PubMed ID: 4633971
    [No Abstract]   [Full Text] [Related]  

  • 11. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
    Lieberman MM; Ayala E
    J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
    [No Abstract]   [Full Text] [Related]  

  • 13. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
    Daoulas-Le Bourdelles F; Berche P; Véron M
    Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment].
    Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF
    Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa.
    Johnston LJ; Syeklocha D
    Can J Microbiol; 1972 Oct; 18(10):1607-11. PubMed ID: 4628185
    [No Abstract]   [Full Text] [Related]  

  • 17. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
    Ding B; von Specht BU; Li Y
    Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection.
    Hirao Y; Homma JY
    Jpn J Exp Med; 1978 Feb; 48(1):41-51. PubMed ID: 97424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
    Jones RJ; Hall M; Ricketts CR
    Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.